Prothena Management

Management criteria checks 2/4

Prothena's CEO is Gene Kinney, appointed in Sep 2016, has a tenure of 7.58 years. total yearly compensation is $7.04M, comprised of 9% salary and 91% bonuses, including company stock and options. directly owns 0.024% of the company’s shares, worth $268.61K. The average tenure of the management team and the board of directors is 7.1 years and 7.6 years respectively.

Key information

Gene Kinney

Chief executive officer

US$7.0m

Total compensation

CEO salary percentage	9.0%
CEO tenure	7.6yrs
CEO ownership	0.02%
Management average tenure	7.1yrs
Board average tenure	7.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Gene Kinney's remuneration changed compared to Prothena's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$7m	US$631k	-US$147m
Sep 30 2023	n/a	n/a	-US$73m
Jun 30 2023	n/a	n/a	-US$141m
Mar 31 2023	n/a	n/a	-US$128m
Dec 31 2022	US$7m	US$601k	-US$117m
Sep 30 2022	n/a	n/a	-US$156m
Jun 30 2022	n/a	n/a	-US$1m
Mar 31 2022	n/a	n/a	US$67m
Dec 31 2021	US$5m	US$573k	US$67m
Sep 30 2021	n/a	n/a	US$69m
Jun 30 2021	n/a	n/a	-US$70m
Mar 31 2021	n/a	n/a	-US$124m
Dec 31 2020	US$3m	US$554k	-US$111m
Sep 30 2020	n/a	n/a	-US$102m
Jun 30 2020	n/a	n/a	-US$91m
Mar 31 2020	n/a	n/a	-US$80m
Dec 31 2019	US$3m	US$538k	-US$78m
Sep 30 2019	n/a	n/a	-US$79m
Jun 30 2019	n/a	n/a	-US$84m
Mar 31 2019	n/a	n/a	-US$128m
Dec 31 2018	US$11m	US$525k	-US$156m
Sep 30 2018	n/a	n/a	-US$181m
Jun 30 2018	n/a	n/a	-US$209m
Mar 31 2018	n/a	n/a	-US$167m
Dec 31 2017	US$5m	US$521k	-US$153m

Compensation vs Market: Gene's total compensation ($USD7.04M) is above average for companies of similar size in the UK market ($USD1.33M).

Compensation vs Earnings: Gene's compensation has increased whilst the company is unprofitable.

CEO

Gene Kinney (54 yo)

7.6yrs

Tenure

US$7,043,826

Compensation

Dr. Gene G. Kinney, Ph D., has been the Chief Executive Officer and President of Prothena Corporation plc since September 26, 2016 and October 3, 2016 respectively and served as its Chief Operating Officer...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Gene Kinney	President	7.6yrs	US$7.04m	0.024% $ 268.6k
Tran Nguyen	CFO & Chief Strategy Officer	11.1yrs	US$2.70m	0.0060% $ 67.2k
Brandon Smith	Chief Operating Officer	2.5yrs	US$2.63m	0% $ 0
Carol Karp	Chief Regulatory Officer	7.3yrs	US$2.57m	0% $ 0
Hideki Garren	Chief Medical Officer	3yrs	US$2.68m	0% $ 0
Karin Walker	Chief Accounting Officer & Controller	10.9yrs	no data	no data
Wagner Zago	Chief Scientific Officer	6.8yrs	US$3.34m	no data
Mark Johnson	Vice President of Investor Relations	no data	no data	no data
Michael Malecek	Chief Legal Officer	no data	US$1.18m	no data
David Ford	Chief People Officer	less than a year	no data	no data
Yvonne Tchrakian	Company Secretary	no data	no data	no data

7.1yrs

Average Tenure

54yo

Average Age

Experienced Management: 0Y3M's management team is seasoned and experienced (7.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Gene Kinney	President	7.6yrs	US$7.04m	0.024% $ 268.6k
Helen Kim	Independent Director	1.7yrs	US$896.63k	0% $ 0
Richard Collier	Independent Director	11.3yrs	US$912.48k	0.0023% $ 25.6k
Daniel Welch	Independent Director	less than a year	no data	no data
Lars Ekman	Independent Chairman	18.9yrs	US$923.48k	0.00045% $ 5.1k
Shane Cooke	Independent Director	11.3yrs	US$354.39k	0% $ 0
Dennis Selkoe	Independent Director	10.8yrs	US$901.73k	0.0078% $ 88.3k
Karl Anders Harfstrand	Independent Director	9.3yrs	US$907.48k	0% $ 0
Paula Cobb	Independent Director	4.8yrs	US$908.48k	0% $ 0
Oleg Nodelman	Independent Director	4.3yrs	no data	no data
William Dunn	Independent Director	less than a year	US$1.70m	no data

7.6yrs

Average Tenure

63yo

Average Age

Experienced Board: 0Y3M's board of directors are considered experienced (7.6 years average tenure).

Prothena Management

Management criteria checks 2/4

Key information

Recent management updates

Prothena Corporation plc, Annual General Meeting, May 14, 2024

Prothena Appoints David Ford to Newly Created Chief People Officer

Prothena Corporation plc Announces Board Changes

Prothena Corporation plc Appoints Billy Dunn to its Board of Directors

Prothena Corporation plc Appoints Helen S. Kim to its Board of Directors

Prothena Corporation plc, Annual General Meeting, May 17, 2022

Recent updates

Prothena Corporation plc, Annual General Meeting, May 14, 2024

Prothena Appoints David Ford to Newly Created Chief People Officer

Full year 2023 earnings released: US$2.76 loss per share (vs US$2.47 loss in FY 2022)

Prothena Corporation plc has filed a Follow-on Equity Offering in the amount of $250 million.

Prothena Corporation plc Announces Board Changes

Full year 2023 earnings released: US$2.76 loss per share (vs US$2.47 loss in FY 2022)

Prothena Corporation plc Provides Earnings Guidance for the Year 2024

Prothena Corporation plc to Report Q4, 2023 Results on Feb 15, 2024

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: EPS: US$0.41 (vs US$0.97 loss in 3Q 2022)

Prothena Corporation plc to Report Q3, 2023 Results on Nov 02, 2023

Prothena Reportedly Prepares for Potential Sale

Prothena Reportedly Prepares for Potential Sale

Second quarter 2023 earnings released: US$1.03 loss per share (vs US$0.88 loss in 2Q 2022)

Prothena Corporation plc to Report Q2, 2023 Results on Aug 03, 2023

Prothena Corporation plc Presents New Research in the Treatment of Alzheimer's Disease At Alzheimer's Association International Conference®? 2023

Prothena C Corporation plc Announces Phase VITAL Clinical Trial Results Published in Blood Showing Survival Benefit in Patients with Mayo Stage IV Al Amyloidosis Treated with Birtamimab

Prothena Corporation plc Appoints Billy Dunn to its Board of Directors

First quarter 2023 earnings released: US$0.89 loss per share (vs US$0.78 loss in 1Q 2022)

Prothena Corporation plc Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: US$2.47 loss per share (vs US$1.51 profit in FY 2021)

Prothena Corporation plc to Report Q4, 2022 Results on Feb 23, 2023

Prothena Corporation plc Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005

Prothena Corporation plc Presents Data Demonstrating Consistent Survival Benefit Observed with Birtamimab in Mayo Stage IV AL Amyloidosis Patients in Phase 3 VITAL Study at ASH 2022

Third quarter 2022 earnings released: US$0.97 loss per share (vs US$2.39 profit in 3Q 2021)

Prothena Corporation plc to Report Q3, 2022 Results on Nov 03, 2022

Prothena Corporation plc Appoints Helen S. Kim to its Board of Directors

Second quarter 2022 earnings released: US$0.88 loss per share (vs US$0.62 profit in 2Q 2021)

Prothena Corporation plc Provides Earnings Guidance for the Year 2022

Prothena Corporation plc to Report Q2, 2022 Results on Aug 08, 2022

Prothena Corporation plc(NasdaqGS:PRTA) dropped from Russell Microcap Value Index

Investor sentiment deteriorated over the past week

Prothena Corporation plc Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer's Disease

Prothena Corporation plc, Annual General Meeting, May 17, 2022

Prothena Corporation plc Announces U.S. Food and Drug Administration Clearance of IND for PRX012, A Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Prothena Corporation plc Provides Earnings Guidance for the Year 2022

Prothena Corporation plc to Report Q4, 2021 Results on Feb 17, 2022

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS US$2.39 (vs US$0.77 loss in 3Q 2020)

Forecast to breakeven in 2021

Second quarter 2021 earnings released: EPS US$0.62 (vs US$0.66 loss in 2Q 2020)

Forecast to breakeven in 2021

Forecast to breakeven in 2021

First quarter 2021 earnings released: US$0.91 loss per share (vs US$0.59 loss in 1Q 2020)

Prothena Corporation plc Provides Earnings Guidance for the Year 2021

Revenue beats expectations

Full year 2020 earnings released: US$2.79 loss per share (vs US$1.95 loss in FY 2019)

Prothena Corporation plc Announces Promising New Preclinical and Clinical Data from Its Neurodegenerative Programs Selected for Oral Presentations At AD/PD 2021

Full year 2020 earnings released: US$2.79 loss per share (vs US$1.95 loss in FY 2019)

Revenue beats expectations

Prothena Corporation plc to Report Q4, 2020 Results on Feb 11, 2021

Prothena Corporation plc Announces Confirmatory Phase 3 AFFIRM-AL Study of Birtamimab in Mayo Stage IV Patients with AL Amyloidosis under SPA Agreement with FDA

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age